Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics的股票在公司宣佈其在加利福尼亞大學舊金山分校的RIDGE-1階段臨床試驗中對首名患者進行了TN-401基因療法給藥後，交易價格上漲。
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics的股票在公司宣佈其在加利福尼亞大學舊金山分校的RIDGE-1階段臨床試驗中對首名患者進行了TN-401基因療法給藥後，交易價格上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間